Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028 (Business Opportunities - Advertising Service)

INNetAds > Business Opportunities > Advertising Service

Item ID 2114722 in Category: Business Opportunities - Advertising Service

Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028

Free Online Advertising
Free Internet Web Site Advertising.

UK Free Classifieds
United Kingdom Free Ads Website.
100% Free Ad Posting.

Canada Free Ads
Popular Online Classifieds in Canada.
No Sign up, No Email Required to Post.

Bharat Book Bureau Provides the Trending Market Research Report on “Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028”under Life Sciences Market Research Report Category. The report offers a collection of superior Market research, Market analysis, competitive intelligence and Market reports.
Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028 Report Highlights:
• Global LAG 3 Inhibitors Market Dynamics
• Clinical Approaches to Target LAG 3 Inhibitors
• Number of LAG 3 Inhibitors Drug In Trials
• LAG 3 Inhibitors Approved Patent Insight
• LAG 3 Inhibitors Trials By Phase, Company, Country, Indication
• Company Agreement/Partnership/Deals For Ongoing Trials
• LAG-3 Targeted Approach in Cancer Therapy
• Therapeutic Approaches for Novel LAG-3 Targeted Therapy
• Global LAG 3 Inhibitor Market Future Outlook
Cancer immunotherapy is a novel approach which can reverse tumor immune escape by suppressing immune checkpoint pathways. Several immune checkpoint inhibitors targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have demonstrated durable efficacy against melanoma, renal, lung and other cancers. However, despite these promising long-term responses, the majority of patients failed to respond to immune checkpoint blockade, demonstrating primary resistance. Additionally, many of these patients who initially respond to treatment eventually experience relapse secondary to acquired resistance.
To mitigate these challenges, researchers have identified several co-stimulatory receptors including lymphocyte activation gene-3 (LAG-3). LAG-3 is a member of the immunoglobulin superfamily (IgSF) and exerts a wide variety of biologic impacts on T cell function. It is expressed on the cell membranes of natural killer (NK) cells, tumor infiltrating lymphocytes (TIL), a subset of T cells, and dendritic cells. Beyond its role in wide range of autoimmune diseases, it also reduces the body’s ability to resist infection and promote chronic infections. Apart from this, the receptor is also over-expressed in several cancers including breast cancer, melanoma, non-Hodgkin lymphoma, myeloma, gastric cancer, and others.
The receptor is considered as a promising target in cancer immunotherapy. Studies have demonstrated that LAG-3 has synergistic action with PD-1 and PD-L1. Although the exact mechanism is unclear, it is shown that its modulation causes a negative regulatory effect over T cell function, preventing tissue damage, and autoimmunity. LAG-3 and PD-1 are frequently co-expressed and upregulated on tumor-infiltrating lymphocytes (TILs) leading to immune exhaustion and tumor growth. The blocking of LAG-3 not nly improves anti-tumor immune responses but also potentiates other forms of immunotherapy given its different mechanism of action mainly mediated by impeding cell cycle progression.
Browse our full report with Table of Content :
About Bharat Book Bureau:
Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 15,00,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Databases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.
Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773

Related Link: Click here to visit item owner's website (0 hit)

Target State: Maharashtra
Target City : Navi Mumbai
Last Update : 07 January 2022 11:02 AM
Number of Views: 54
Item  Owner  : Priya Prakash
Contact Email:
Contact Phone: 22 27810772 / 27810773

Friendly reminder: Click here to read some tips.
INNetAds > Business Opportunities > Advertising Service
 © 2022
2022-10-06 (0.402 sec)